Holen Sie sich die Stockscreener-App
13.24
2.43%
-0.33
Handel nachbörslich:
13.25
0.010
+0.08%
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
10x Genomics to Acquire Scale Biosciences - SynBioBeta
Brookdale, Evolent Health, Fortrea, 10x Genomics, and Organon Stocks Trade Up, What You Need To Know - Yahoo Finance
10X Genomics’ SWOT analysis: genomics firm’s stock faces funding headwinds - Investing.com
Earnings Beat: 10x Genomics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
10X Genomics Q2 Earnings Call Highlights: Balancing Growth and Challenges with Strong China Performance and Favorable Bruker Settlement - AInvest
Price Floor Holding on 10x Genomics Inc. — Rebound PossibleBuy Alerts With Low Risk Confirmation Noted - sundaytimes.kr
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know - Yahoo Finance
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know | FinancialContent - FinancialContent
Does 10x Genomics Inc. offer margin of safetyFree Weekly Earnings Watchlist - thegnnews.com
10x Genomics, Inc. (NASDAQ:TXG) Q2 2025 Earnings Call Transcript - Insider Monkey
Zacks.com featured highlights include Tsakos Energy Navigation Limited, 10x Genomics, Pan American Silver, Wolverine World Wide and Interface - TradingView
Will Breakout in 10x Genomics Inc. Sustain Through Next WeekIntraday Trend Analysis for Fast Gains Released - beatles.ru
10x Genomics Sees Strong Growth with Q2 Results, Strategic Acquisition, and Optimistic Outlook - AInvest
Why 10x Genomics (TXG) Is Down 6.0% After Tariff-Driven Q2 Revenue Surge and Guidance Update - simplywall.st
10x Genomics shares rise 1.71% after-hours following Q2 revenue beat and Deutsche Bank price target adjustment. - AInvest
10x Genomics: UBS maintains a 'Neutral' Rating, The Target Price is $13 - AInvest
10x Genomics: UBS maintains Neutral rating, raises PT to $13 from $12. - AInvest
10x Genomics shares fall 4.65% intraday after reporting Q2 revenue of $172.9M, below analyst estimates of $139.4M. - AInvest
10x Genomics (NASDAQ:TXG Shareholders Incur Further Losses as Stock Declines 4.8% This Week, Taking Five-year Losses to 88% - 富途牛牛
Why 10x Genomics (TXG) Stock Is Falling Today - FinancialContent
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics (NASDAQ:TXG) Reports Upbeat Q2, Stock Soars - Yahoo Finance
10x Genomics Inc (TXG) Q2 2025 Earnings Call Highlights: Navigating Revenue Shifts and ... By GuruFocus - Investing.com Canada
10x Genomics Inc (TXG) Q2 2025 Earnings Call Highlights: Navigat - GuruFocus
10x Genomics: Q2 Earnings Snapshot - Stamford Advocate
10x Genomics Invests in the Future with Scale Biosciences Acquisition, Eyes Scalable Growth - geneonline.com
10X Genomics Outpaces Estimates And Returns To Profit - Finimize
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
10X Genomics' Q2 revenue beats estimates - MarketScreener
10x Genomics to acquire Scale Biosciences to expand single cell analysis By Investing.com - Investing.com Australia
10x Genomics to acquire Scale Biosciences to expand single cell analysis - Investing.com
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q2 Revenue $172.9M, vs. FactSet Est of $139.4M - MarketScreener
(TXG) 10x Genomics, Inc. Expects Q3 Revenue Range $140.0M$144.0M - MarketScreener
10x Genomics Reports Second Quarter 2025 Financial Results - Finansavisen
10x Genomics To Acquire Scale Biosciences - Barchart.com
Transcript : 10x Genomics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings To Watch: 10x Genomics (TXG) Reports Q2 Results Tomorrow - Yahoo Finance
10x Genomics Inc. Recovery Potential Based on Technical ToolsScalable Portfolio Growth Suggestions Released - metal.it
Is 10x Genomics Inc. a growth stock or a value stockHigh-octane investment opportunities await - Jammu Links News
What is the dividend policy of 10x Genomics Inc. stockOverwhelming profit margins - Jammu Links News
What are analysts’ price targets for 10x Genomics Inc. in the next 12 monthsFree Predictions - Jammu Links News
Is 10x Genomics Inc. stock overvalued or undervaluedDynamic profit opportunities - Jammu Links News
What catalysts could drive 10x Genomics Inc. stock higher in 2025Remarkably fast returns - Jammu Links News
What are 10x Genomics Inc. company’s key revenue driversAchieve breakthrough performance with smart picks - Jammu Links News
What is the risk reward ratio of investing in 10x Genomics Inc. stockBuild wealth with steady, reliable stocks - Jammu Links News
What institutional investors are buying 10x Genomics Inc. stockRobust investment performance - Jammu Links News
10x Genomics' (TXG) "Sell (E+)" Rating Reiterated at Weiss Ratings - MarketBeat
When is 10x Genomics Inc. stock expected to show significant growthDaily Trading Signals That Work - Jammu Links News
Options Data Show Bullish Bias in 10x Genomics Inc.Smart Money Tracking Signal Generator Activated - metal.it
Building trade automation scripts for 10x Genomics Inc.Low Risk Picks for Daily Trading Released - metal.it
10x Genomics Inc. Recovery Likely Here’s What Data ShowsFree Signals Group - beatles.ru
10x Genomics Inc. Price Targets Raised After ReboundWeekly Setup With 3x Return Potential Published - metal.it
10x Genomics Inc. Stock Lags Behind Sector BenchmarksInvestment Plan With Growth Optimization Finalized - beatles.ru
PacBio, 10x Genomics, QuidelOrtho, STAAR Surgical, and Clover Health Stocks Trade Down, What You Need To Know - TradingView
Why 10x Genomics Inc. stock attracts strong analyst attentionReliable Investment Entry Signals Confirmed by Charts - beatles.ru
1.47%
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):